we Magee-Womens ovarian to a over regarding I everyone. ago just that the like significant retrospective few made X morning, begin we recap successful morning that a years. good and the study past would completed Glenn, Hospital you, multiyear announcement with this UPMC Thank a conducted of with cancer weeks
responses we patient of pursue of biomarkers Society offering expanded that predict presented independently result outcomes learning to can drug have study, the June, our oncology. the Annual Oncology which a novel in discovery American were Meeting intelligence artificial machine and findings in this and As of Clinical at the of
that we been not With by play unique and discovering partners, positioned discovery playing active significant potential capabilities, have own more a already very are well in to a role development. drug biomarkers and discovered in our also and biomarkers role, these validating in only direct but
recall the features inputs, XXX key used study that drug to ovarian Please serious overall the very ovarian and cancer whole-transcriptome of very designed endpoints patients recurrence. XXXX was models XXX including a type the in sequencing, This data from profile a Magee broad included that of to were data, with cancer, response train that identify included through study high survival drive were cancer rate from profiles pathology sequencing, XXXX, whole-exome in array patient digital study. a
were biomarker during development. previewed first conference to and supports obtain novel an that discovery call, able data our end-of-life ovarian we quarter cancer As we
to We tumor patient our were artificial a represents are machine we biobank of to machine degree preserved to ovarian intelligence samples of where the and accuracy. our strong predict deliver capabilities, we and to accuracy, high our diverse a predictive extension ability able learning drugs very learning very employ natural report identify This within core in our with active high responses demonstrated prognostic pleased with to subgroups progress patient population. cancer of models that levels capabilities extensive
potential overall now to our for survival approaches further which, pathology differentiating are includes features and in discovery are our digitized ability drug deep step biomarker We themselves, biomarkers. this learning This taking slides, state-of-the-art of applying extract responses. by one from and both for
capabilities, and in pursue to discovery further as us enables independently a the accelerate methodology now extend or biopharma with patient deep companies. platform learning either our our stratify and initial biomarker stages partnership to cohorts Our of
of significant represents cancer all ovarian deadliest epithelial in the being with a oncology, unmet need cancer gynecologic Ovarian malignancies.
in chemotherapy XX% front-line ultimately are approximately which While incurable. disease percentage, cases, in to these of is equal experience an will women these relapse cancers sensitive
to These sequence the and decision be Outside beyond no treatment outside universal oncology. extend the discovery determine ovarian well for is for agent, as agents. cancer capabilities chemotherapeutic in there and can of well standard diseases of used timing chemotherapy, other cancer types primary path biomarkers of of care of as the
External valued sources billion at XXXX. the have market $XX in discovery biomarker more than
while with opportunity is So capabilities role this leading play leverage significant validating of a to further of next-generation our value unique health the to our partners and forward assets to for shareholders. biopharmaceutical a these networks. through care We development very therapeutics, for and collaborations discovery creating us enduring in look set capabilities
can launched second tissue the more human architecture for and selection by its biomarker addition our cell than extracellular drug this clinical XD organ-specific to does creates for development. during a be quarter, culture robust optimize Also, to tumor clinical testing It allows a critical candidates. more more in and assays. closely interactions vivo XD method a and subsequent cellular mimics predictions we in of surroundings candidate novel and used that representative discovery for for clinical between outcomes initiative, preserving technology This
trials. in drug is by are in third new $X.X XD annually XX% parties testing to the time-consuming cell and for XXXX. decrease but benefits need time XXXX to The estimated to They development billion potential billion market, and $X.X numerous. developers reducing to animal also grow drug The of market iterations during from the the cost clinical
development. biobank you informed probability in earlier tumor by type is to selections tumor have success leverages and known Also platform, drug evaluate toward to also is was to novel ACE Oncology's The as as program remember, with and designed early-stage worth Predictive initiative. of intelligence groups progress facilitate our program, artificial and drug may increase our through academic Compound ACE is mentioning discovery samples. tumor of access This the institutions know, to heterogenous as Exploration future addressing combinations more which, diverse universities partnerships the geared and enable investigators you otherwise to of Accelerating academic the created program, development compounds efficiently extensive provide heterogeneity that with made clinical academic we their
the and This program, of Core University collections than largest meticulously is we Middle the the one been at a created for viable has The This University United in collaboration is Discovery of which Dr. library of past of Antarctic. which resulted States. America, the strains Michigan's Sherman Michigan's of constructed the East, University first decade, Michigan. extracts North more Products have been has of H. Institute, the over pharmaceutically with library, in Asia laboratory year, Natural nurturing from Life of in Sciences by David South our America the Pacific, comprised
discovery. Oncology's represents collaboration this true importantly, Most Predictive foray drug into
natural on and and drug of are we Michigan's molecule new discovery come reduction that to development the our more candidates, using capabilities small opportunities will molecule our emerge, to runway. Several that positioned include and to very strategic large well operations platform. our publications and implemented initiative.
To cash University initiative With streamlining ensure we products recently ML other our aimed and that AI definitely of continue we out addition a we capitalize this able proprietary this cost models expand at of drug extending remain nimble announced and of comprehensive to
which, operations, made a our decision also As which Pittsburgh, serves as we consolidate our challenging business, you part initiative, into headquarters. the of houses know, as Birmingham corporate key our Biologics this to
the this important From context action. of a understand strategic perspective, it is to
company to its capabilities is remain First to drive laser focused respect to with it application intelligence of incumbent the on core drug and on the discovery. foremost, artificial
the pristine quality Second, model such of outcomes predict that thing accuracy enables has our to and those tumor very the with drug data that ability longitudinal identify is the the our been biobank the in tumor from samples. of responses predict generated and biomarkers significance and samples
ongoing Oncology. deliver accuracy pathology of characterizing, of and on and has our is AI-generated our drug sequencing, been at presented precision requires the effort response The to This This are ability and predictions the our data drives now tissue and the and with of externally which which was samples, models constant curating of slides. perfected. models one Association validated an digitization Surgical relevance
marketplace. endeavors, the ourselves possibly of silent the absence cannot In in these we distinguish
case, of the resources reallocation All of dedicated from those and Birmingham in resources Pittsburgh. to this requires this
activities is Lastly, this year, our with approximately the to XX% value roughly our expected once $X.X initiative, operating of to annually, value, activities By company XXXX in innovation company. and equates to $XX.X creation, to signaling core our implemented adding based by significance million. used perpetuates adding million of of This reduce our market relevance which cash in on fully cash cash burn are for in operating the of to the run stated our QX assets. used impacts the rate respect valuation of value we
XXXX, net a and point loss Birmingham revenue. $X.X of $X.X generated segment preference, of XXXX in million in a As de-minimis-supporting with million the
not our Pittsburgh for to moving over strengthen further last to We in our since Senior the right $X.X simply lack of of decision through X.X company has million Dr. capital become financial the leadership million XXX,XXX to and costs of proceeds shares. net the we've Birmingham, and Birmingham its years million, the inducement in bolster to essential of forward. gratitude facility partners significant profitability, be cash $X.X raises, announced our of over company core especially in million Biologics, of exercise additional our light And May, focus you, Larry our $X.X of couple raised his a Larry.
To in runway. through President dedication. and raised issuance through in million million issuance Vice this company the our our through sheet Moreover, and warrant an transaction. DeLucas, in Thank extend months the of position, the the shareholders $X.X proceeds remiss helped few In became that $X.X also time, or in for would gross balance extend July, at-the-market net total, its of warrants
this financials our detail. Chief would review now to to call second Josh? Josh I turn quarter Financial Blacher, like And to Officer, over our in
